

Digestive Manifestations in Patients Hospitalized with COVID-19

Supplementary materials

patients without pre-existing digestive disorders	pg. 2
Prevalence and distribution of gastrointestinal symptoms in patients not known to have received COVID-19 treatments with potential gastrointestinal side-effects	pg. 3
Prevalence and distribution of liver test abnormalities in patients without pre-existing liver disease	pg. 4
Prevalence and distribution of liver test abnormalities in patients not known to have received COVID-19 treatments with potential hepatotoxicity	pg. 5
Prevalence and distribution of gastrointestinal symptoms by study site	pg. 6
Potential covariates for primary regression analysis	pgs. 7-8
Programming code for final primary regression model	pgs. 9
Data collection form:	pgs. 10-20


Prevalence and distribution of gastrointestinal symptoms in 1860 patients without preexisting luminal gastrointestinal or pancreaticobiliary disease, compared to the full cohort:






	Excluding patients with	Full cohort
	luminal gastrointestinal	(N=1992)
	or pancreaticobiliary	
	disease (n=1860)	
Any gastrointestinal	969	1052
symptom	(52%)	(53%)
Diarrhea	622	674
	(33%)	(34%)
Nausea	493	537
	(27%)	(27%)
Vomiting	283	312
	(15%)	(16%)
Abdominal pain	196	228
	(11%)	(11%)


Prevalence and distribution of gastrointestinal symptoms in 875 patients who were not known to have received any of the following medications that are associated with potential gastrointestinal side-effects: hydroxychloroquine, chloroquine, remdesivir, oseltamivir, lopinavir/ritonavir, and interferon alpha, compared to the full cohort:






	Excluding patients known to have received COVID- 19 treatments with gastrointestinal side effects (n=875)	Full cohort (N=1992)
Any gastrointestinal	412	1052
symptom	(47%, 95%CI 44-50%)	(53%, 95%CI 51-55%)
Diarrhea	248	674
	(28%)	(34%)
Nausea	199	537
	(23%)	(27%)
Vomiting	128	312
_	(15%)	(16%)
Abdominal pain	95	228
	(11%)	(11%)


Prevalence and distribution of liver test abnormalities in 1876 patients without preexisting liver disease, compared to the full cohort:






	Excluding patients with prior liver disease (n=1876)	Full cohort (N=1992)
Highest ALT or TB abnormal	639 (34%)	695 (35%)
Mild	354 (19%)	387 (19%)
Moderate	137 (7%)	150 (8%)
Severe	148 (8%)	158 (7%)


Prevalence and distribution of abnormal liver tests in 1825 patients who were not known to have received any of the following medications with potential hepatotoxicity: remdesivir, oseltamivir, lopinavir/ritonavir, interferon alpha, compared to the full cohort:





	Excluding subjects known to have received COVID- 19 treatments with potential hepatotoxicity (n=1825)	Full cohort (N=1992)
Highest ALT or TB	612	695
abnormal	(34%)	(35%)
Mild	344	387
	(19%)	(19%)
Moderate	133	150
	(7%)	(8%)
Severe	135	158
	(7%)	(8%)

Prevalence and distribution of digestive manifestations and liver test abnormalities by site:



Potential covariates that were considered for the primary regression analysis:

		Mechanical Ventilation or Death n=760	No Mechanical Ventilation or Death n=1232	p-value
Age, mean (SD)		64.1 (15.1)	57.6 (16.5)	<.0001
Sex, n (%)	Male	464 (61.1)	664 (53.9)	0.0017
	Female	296 (38.9)	568 (46.1)	
Race, n (%)	American Indian/Alaska Native	2 (0.3)	3 (0.2)	0.1938
	Asian	35 (4.6)	35 (2.8)	
	Black/African American	327 (43)	515 (41.8)	
	White	281 (37)	451 (36.6)	
	Multiple	3 (0.4)	7 (0.6)	
	Unknown	112 (14.7)	220 (17.9)	
Cigarette smoking status, n (%)	Current/Ex- smoker	306 (40.3)	389 (31.6)	<.0001
	Non-smoker	383 (50.4)	792 (64.3)	
	Unknown	71 (9.3)	51 (4.1)	
Alcoholism, n (%)	Current/Prior	93 (12.2)	178 (14.4)	<.0001
	No	547 (72)	953 (77.4)	
	Unknown	120 (15.8)	101 (8.2)	
Obesity, n (%)	No	381 (50.1)	643 (52.2)	0.3715
	Yes	379 (49.9)	589 (47.8)	
Body mass index, mean (SD)		31.8 (8.9)	31.3 (8.2)	0.2681
Hypertension, n (%)	No	226 (29.7)	521 (42.3)	<.0001
	Yes	534 (70.3)	711 (57.7)	
Diabetes, n (%)	No	448 (58.9)	822 (66.7)	0.0005
	Yes	312 (41.1)	410 (33.3)	
Cardiac disease, n (%)	No	557 (73.3)	1000 (81.2)	<.0001
	Yes	203 (26.7)	232 (18.8)	

		Mechanical Ventilation or Death n=760	No Mechanical Ventilation or Death n=1232	p-value
Pulmonary disease, n (%)	No	591 (77.8)	987 (80.1)	0.2091
	Yes	169 (22.2)	245 (19.9)	
Immunocompromised, n (%)	No	645 (84.9)	1082 (87.8)	0.0591
	Yes	115 (15.1)	150 (12.2)	
Active/Current malignancy, excluding non-melanoma skin cancer, n	No	704 (92.6)	1165 (94.6)	0.0821
(%)	Yes	56 (7.4)	67 (5.4)	
Moderate to severe kidney disease (creatinine >3 mg/dL prior to	No	663 (87.2)	1141 (92.6)	<.0001
admission, end stage renal disease or dialysis, n (%)	Yes	97 (12.8)	91 (7.4)	
Luminal gastrointestinal disease, n (%)	No	740 (97.4)	1168 (94.8)	0.0057
	Yes	20 (2.6)	64 (5.2)	
Chronic liver disease, n (%)	No	737 (97)	1200 (97.4)	0.5704
	Yes	23 (3)	32 (2.6)	
Recent (within 1 month of admission) or current (at admission)	Yes	232 (30.5)	364 (29.5)	0.0008
ACE or ARB use, n (%)	No	501 (65.9)	854 (69.3)	
	Unknown	27 (3.6)	14 (1.1)	
Recent (within 1 month of admission) or current (at admission)	Yes	190 (25)	337 (27.4)	0.0193
NSAIDs use, n (%)	No	425 (55.9)	718 (58.3)	
	Unknown	145 (19.1)	177 (14.4)	
Recent (within 1 month of admission) or current (at admission)	Yes	235 (30.9)	317 (25.7)	<.0001
PPI or H2 blocker use, n (%)	No	451 (59.3)	860 (69.8)	
	Unknown	74 (9.7)	55 (4.5)	
Recent (within 1 month of admission) or current (at admission)	Yes	241 (31.7)	346 (28.1)	<.0001
Antibiotics use, n (%)	No	472 (62.1)	852 (69.2)	
	Unknown	47 (6.2)	34 (2.8)	

Programming code for final primary regression model

The final primary model was developed by manual selection of variables based on univariate analyses, followed by examination of the Akaike Information Criterion (AIC) as potential variables were added and removed from the model.

```
proc logistic data=dmc19 ;
    class covid_severe gastro_symp (ref='No') liver_injury (ref='None')
        comorb_gastrodis (ref='No') comorb_kidney (ref='No')
        comorb_hypert (ref='No') alcoholic (ref='No')
        smoke (ref='Non-smoker') sex ppi_h2 (ref='No')
        recent_antibiotics (ref='No')/param=ref;
    model covid_severe (event='Yes') = gastro_symp liver_injury
        comorb_gastrodis comorb_kidney comorb_hypert age alcoholic smoke
        sex ppi_h2 recent_antibiotics/ lackfit;
run;
```

Data collection form:

The electronic data collection form contained 216 items and was divided into 5 sections: 1) patient characteristics; 2) COVID-19 parameters; 3) symptomatology; 4) imaging and endoscopy; and 5) laboratory data and other hepatic considerations. The form was developed by a core group of investigators and was refined and finalized after a 72-hour period of public comment.

DMC19 Registry Instructions 4_17_20

- 1) Please complete the below data collection form (DCF) in REDCap at the **time of discharge or death**. Data will appear in the DMC19 database once entry and verification are complete.
- 2) We aim to capture **inpatients** with a confirmed COVID-19 diagnosis, **regardless of whether they have digestive manifestations**. After prevalence is defined in hospitalized patients, and as the numbers grow, we may focus on patients who are known to have GI manifestations and/or include outpatients.
- 3) Please make all efforts to collect data on the **first 50-100 consecutive** patients at your hospital or health system.
- 4) Eligible patients can and should be identified by any means necessary, which may include, but is not limited to, institutional laboratory records, data warehouse queries, electronic health record research subject identification tools/dashboards, and discussions with the infectious disease or critical care services, etc. You may elect to use the emergency ICD-10 code of U07.1 2019-nCov acute respiratory disease to help identify eligible patients.
- 5) Please **triple check** data for accuracy before submission. Although we are performing central data monitoring, we cannot verify incoming data against source documents, nor are we performing on-site monitoring visits. Therefore, the overall quality of the data is assured primarily at the site level.
- 6) Along the lines of #5, coordinators should confer with a clinician during data collection to ensure that clinical context is accounted for as much as possible in the interpretation of questions that involve an element of subjectivity.
- 7) All data fields should have affirmative, negative, and unknown options. Therefore, missing data will be assumed to be inadvertent and this will generate a query.
- 8) Please maintain a secure key at your site that allows patient identification on the basis of subject ID#. This may be used in the future for to collect data pertaining to long-term outcomes.

Subject ID #	
Institution	
Email address (of individual entering data)	
Patient characteristics	
Age (years)	
Sex	□Male

	□Female
	- Pregnant
	- Not pregnant
	- Unknown
Race (check all that apply)	□American Indian or Alaska Native
Trace (erroen an arat appry)	□Asian
	□Black or African American
	□Native Hawaiian or other Pacific Islander
	□White
	□Unknown
Ethnicity	☐Hispanic or Latino
Luminoity	□Not Hispanic or Latino
	Unknown
Rody mass index at presentation (kg/ms):	□Yes
Body mass index at presentation (kg/m ₂): available?	
avaliable?	☐Cannot calculate, but obesity documented
Dody many index of proportation (leg/m)	□Cannot calculate
Body mass index at presentation (kg/m ₂)	
Is the patient a health care worker?	□Yes
	□No
	□Unknown
Cigarette smoking status	□Current smoker
	□Ex-smoker
	□Non-smoker
	□Unknown
Vaping status	□Current vaping
	□Prior vaping
	□Does not vape
	□Unknown
Alcoholism	□Yes, current
	□Prior
	□No
	□Unknown
Cannabis use	□Current user
	□Prior user
	□No
	□Unknown
Illicit drug use	□Current user
_	□Prior user
	□No
	□Unknown
Comorbidities (select all that apply)	□Hypertension
()	□Coronary artery disease/prior or current
	myocardial infarction (MI)
	☐Congestive heart failure (CHF)
	☐Chronic pulmonary obstructive disease (COPD)
	□Asthma

	□Obstructive sleep apnea (OSA) □Interstitial lung disease (ILD)/pulmonary fibrosis □Peripheral vascular disease (PVD) □Prior or current cerebrovascular accident (CVA) or transient ischemic attack (TIA) □Dementia □Collagen vascular/rheumatologic disease □Chronic liver disease - Alcoholic liver disease - Non-alcoholic fatty liver disease (NAFLD) - Hepatitis C virus - Hepatitis B virus - Other, specify □Cirrhosis If yes, MELD score prior to COVID-19 illness □Diabetes mellitus, uncomplicated □Diabetes mellitus with end-organ damage □Moderate to severe kidney disease (creatinine >3 mg/dL prior to admission, end stage renal disease [ESRD], dialysis) □Active/Current malignancy, excluding non- melanoma skin cancer If yes, specify □Prior malignancy □Human immunodeficiency virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) □Solid organ transplant recipient □Bone marrow transplant recipient □Bronic diarrhea □Chronic diarrhea □Chronic diarrhea □Chronic constipation □Celiac disease □Prior biliary disease, including cholelithiasis, cholecystitis, choledocholithiasis or cholangitis □Prior pancreatitis □Recurrent acute pancreatitis □Chronic pancreatitis □Chronic pancreatitis □Chronic pancreatitis □Chronic pancreatitis □Chronic pancreatitis
	□None
If all an analy	□Other, not fitting into an above category
If other, specify	
Recent (within 6 months) or current (at	□Yes
admission) immunosuppression or	□No
chemotherapy	□Unknown

If yes, specify	(medication, dose, route, duration)
Recent (within 1 month of admission) or	□Yes
current (at admission) ACE inhibitor use	□No
	□Unknown
Recent (within 1 month of admission) or	□Yes
current (at admission) angiotensin	□No
receptor blocker (ARB) use	□Unknown
Recent (within 1 month of admission) or	□Yes
current (at admission) NSAIDs use	□No
	□Unknown
Recent (within 1 month of admission) or	□Yes
current (at admission) antibiotic use	□No
	□Unknown
Recent (within 1 month of admission) or	□Yes
current (at admission) PPI use	□No
	□Unknown
Recent (within 1 month of admission) or	□Yes
current (at admission) H2 blocker use	□No
	□Unknown
001/10 /0	
COVID-19 parameters	
History of known contact with COVID-19	□Yes
positive individual(s)	□No
	□Unknown
Highest level of care	□Inpatient ward
	☐Intensive care unit (ICU)
Duration of symptoms prior to first	
seeking medical attention (days)	
Duration of symptoms prior to	
hospitalization (days)	
Duration of hospitalization (days)	
If admitted to ICU, duration of ICU stay	
(days)	
Required mechanical ventilation	□Yes
	□No
Required extracorporeal membrane	□Yes
oxygenation (ECMO)	□No
Required vasopressor support	□Yes
	□No
Final discharge disposition	□Recovered (or almost recovered)
	□Discharged to rehab or nursing facility
	□Deceased
COVID-specific treatments (select all that	□Remdesivir
apply)	□Hydroxychloroquine
	□Chloroquine

	□Azithromycin
	□Glucocorticoids
	□Interferon alpha
	·
	□Intravenous immunoglobulin (IVIG)
	□Lopinavir/ritonavir
	□Oseltamivir
	□Tocilizumab
	□Convalescent plasma
	□None
W 41	Other
If other, specify	(medication, dose, route, duration)
Symptomatology	
Respiratory or systemic symptoms (select	□Fever (subjective or objective)
all that apply)	□Chills/rigors
	□Fatigue or subjective weakness
	□Myalgia
	Sore throat
	□Rhinorrhea (runny nose)
	□ Cough
	□Sneezing
	□Sputum production
	☐Shortness of breath
	- At rest
	- On exertion
	- Not specified
	□Chest tightness or pain
	□Headache
	☐Confusion or altered mental status
	□Loss of smell
	□Loss of taste
	□None
	□Other
If other, specify	
Gastrointestinal symptoms or signs	□Anorexia
(select all that apply)	□Nausea
(□Vomiting
	□Abdominal pain (including cramps)
	-Diffuse
	-Periumbilical
	-Epigastric
	-Right upper quadrant (RUQ)
	-Left upper quadrant (LUQ)
	-Right lower quadrant (RLQ)
	-Left lower quadrant (LLQ)

	-Not specified
	□Diarrhea
	-Maximum number of bowel movements in a 24
	hour period Not documented
	□Bloody diarrhea
	-Maximum number of bowel movements in a 24
	hour period Not documented
	□Hematemesis
	□Melena
	☐Hematochezia (inc. bright red blood per rectum)
	□Dysphagia
	□Odynophagia
	□Constipation
	□Hiccups
	□Jaundice
	□None
	□Other
If other, specify	
Timing of gastrointestinal symptoms (if	☐GI symptom(s) preceded other symptoms
any) relative to respiratory/systemic	☐GI symptom(s) followed other symptoms
symptoms (if any)	□Gl symptom(s) came on concurrently with
, , , , , , , , , , , , , , , , , , , ,	other symptoms
	☐GI symptoms were the only manifestation
	□Can't tell from medical records review
Duration of gastrointestinal symptoms	☐GI symptom(s) were present for a short portion
	(<25% of the duration) of the entire COVID-19
	illness
	☐GI symptom(s) were present for significant
	portion (25-75% of the duration) of the entire
	COVID-19 illness
	☐ GI symptom(s) were present for the
	entire/almost entire COVID-19 illness
	□Can't tell from medical records review
Did gastrointestinal symptoms remain	□Yes
after resolution of other COVID-19	□No
symptoms?	□Unknown
If yes, how long (days)	
Prominence of gastrointestinal symptoms	☐GI symptoms were less prominent than other
	symptoms related to COVID-19
	☐GI symptoms were equally prominent to other
	symptoms related to COVID-19
	☐GI symptoms were more prominent than other
	symptoms related to COVID-19
	□Can't tell from medical records review
Were digestive manifestations	□Yes, GI symptoms
(gastrointestinal or hepatic) specifically	□Yes, LFT abnormalities

addressed in the Assessment/Plan	
section of any progress notes for 3 or	
more days during the hospitalization?	
Did the gastroenterology or hepatology	
service consult on the patient during the	
hospitalization, as evidence by consult	
notes?	
Were stool studies other than FOBT	
(fecal occult blood test) obtained during	
the hospitalization?	
Gastrointestinal diagnoses established □Esophagitis/esophageal ulcers	
shortly before, during, or shortly after	
COVID-19 illness (select all that apply)	ım)
New enteritis \	,
□New colitis	
□Biliary disease, including cholelithiasis,	
cholecystitis, choledocholithiasis or cholangi	tis
□Hepatitis	
□Pancreatitis	
□None	
□Other	
If other, specify	
Was COVID-specific treatment prescribed ☐Yes	
specifically for digestive manifestations?	
□Unknown	
Imaging and endoscopy	
Was abdominal computed tomography ☐Yes	
(CT) performed and abnormal shortly	
before, during, or shortly after COVID-19	
illness?	
If yes, list abnormal findings in the	
impression section of the most	
concerning CT report	
Was abdominal magnetic resonance	
imaging (MRI) performed and abnormal No	
l ala authr la afaire alruinear air ala authr aftair I 🖂 lial ca arrus	
shortly before, during, or shortly after	
COVID-19 illness?	
COVID-19 illness? If yes, list abnormal findings in the	
COVID-19 illness? If yes, list abnormal findings in the impression section of the most	
COVID-19 illness? If yes, list abnormal findings in the impression section of the most concerning MRI report	
COVID-19 illness? If yes, list abnormal findings in the impression section of the most	

If yes, list abnormal findings in the	
impression section of the most	
concerning US report	
Was endoscopy performed during COVID-19 illness? (select all that apply)	□Yes – upper endoscopy (EGD) □Yes – colonoscopy or flexible sigmoidoscopy □Yes – enteroscopy (balloon or push) □Yes – capsule endoscopy □Yes – ERCP □Yes – endoscopic ultrasound (EUS) □No □Unknown
If performed, how many total endoscopic	
sessions did the patient undergo? (EGD+colonoscopy or EUS+ERCP at the same time is considered 1 session)	
If performed, did the patient require	□Yes – nasal cannula
respiratory support BEFORE their first	□Yes – high-flow oxygen
procedure? (select all the apply)	☐Yes – non-invasive positive pressure ventilation
	□Yes – mechanical ventilation
	□Yes – mechanical ventilation, proned
	□Yes – extracorporeal membrane oxygenation (ECMO)
	□No
	□Unknown
If performed, what kind of anesthesia did	Conscious sedation
the patient receive DURING their first procedure? (select all that apply)	☐Deep sedation/monitored anesthesia care (MAC)☐General endotracheal anesthesia
procedure : (Select all triat apply)	□No sedation
	□Unknown
If performed, did the patient experience	☐ Yes – Mild to moderate respiratory compromise
an adverse cardiopulmonary event	☐ Yes – Severe respiratory compromise
related to any of the endoscopic	☐ Yes – Congestive heart failure/cardiomyopathy
procedures? (select all that apply)	☐Yes – Myocardial infarction
	□No
	□Unknown
Endoscopic findings (please list abnormal	
findings in impression section of	
endoscopy report(s)) Histologic findings (please list abnormal	
findings in impression section of	
pathology report(s))	
[]	1
Laboratory data and other hepatologic of	onsiderations
Prior to COVID-19, ideally when patient	
was healthy:	

White blood cells (WBC)	
Hemoglobin	
Platelets	
Aspartate aminotransferase (AST)	
Alanine aminotransferase (ALT)	
Alkaline phosphatase (ALK-phos)	
Total bilirubin	
International normalized ratio (INR)	
Albumin	
Factor V level	
Lipase	
Creatinine	
At time of hospital admission:	
White blood cells (WBC)	
Hemoglobin	
Platelets	
Aspartate aminotransferase (AST)	
Alanine aminotransferase (ALT)	
` '	
Alkaline phosphatase (ALK-phos)	
Gamma-Glutamyl Transferase (highest) U/L	
·	
Total bilirubin	
Direct bilirubin	
International normalized ratio (INR)	
Albumin	
Factor V level	
Lipase	
- What is the upper limit of normal	
Amylase	
- What is the upper limit of normal	
Creatinine	
Highest or lowest level during illness:	
WBC (highest and lowest)	
Hemoglobin (lowest)	
Platelets (lowest)	
AST (highest)	
ALT (highest)	
ALK-phos (highest)	
Gamma-Glutamyl Transferase (highest)	
U/L	
Total Bilirubin (highest)	
Direct Bilirubin (highest)	
INR (highest)	
Albumin (lowest)	
Factor 5 (lowest)	
Lipase (highest)	

- What is the upper limit of normal	
Amylase (highest)	
- What is the upper limit of normal	
Creatinine (highest)	
Absolute lymphocyte count (lowest)	
C-Reactive Protein (CRP) (highest)	
Procalcitonin (highest)	
Troponin (highest)	
Ferritin (highest) ng/mL or ug/L	
Interleukin-6 (highest) pg/mL	
Duration between first onset of symptoms	
,	
and highest AST (days)	
Duration between first onset of symptoms	
and highest ALT (days)	
Duration between first onset of symptoms	
and highest total bilirubin (days)	
Duration between first hospital day and	
highest AST (days)	
Duration between first hospital day and	
highest ALT (days)	
Duration between first hospital day and	
highest total bilirubin (days)	
Abnormal LFTs were	☐Still close to max at discharge/death
	□Improved but not resolved at discharge/death
	□Resolved or close to resolved at discharge/death
···	□Not applicable
Were the increased LFTs suspected to be	□Yes
due to a drug reaction (based on review	□No
of progress/consult notes)?	□Unclear based on records
If yes, which medication(s) were	
If yes, which medication(s) were suspected	☐Unclear based on records (medication, dose, route, duration)
If yes, which medication(s) were suspected If yes, was this a COVID-specific	□Unclear based on records (medication, dose, route, duration) □Yes
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase	□Unclear based on records (medication, dose, route, duration) □Yes □No
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of	□Unclear based on records (medication, dose, route, duration) □Yes
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)?	□Unclear based on records (medication, dose, route, duration) □Yes □No
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of	□Unclear based on records (medication, dose, route, duration) □Yes □No
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)?	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)?	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)?	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)? Anti-HAV IgM	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative □Not checked
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)? Anti-HAV IgM	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative □Not checked □Positive
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)? Anti-HAV IgM	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative □Not checked □Positive □Negative □Negative
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)? Anti-HAV IgM Anti-HCV	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative □Not checked □Positive □Negative □Negative □Negative □Negative □Negative □Negative
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)? Anti-HAV IgM Anti-HCV	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative □Not checked □Positive □Not checked □Positive □Not checked □Positive
If yes, which medication(s) were suspected If yes, was this a COVID-specific treatment that was believed to increase LFTs (based on review of progress/consult notes)? Anti-HAV IgM Anti-HCV	□Unclear based on records (medication, dose, route, duration) □Yes □No □Unclear based on records □Positive □Negative □Not checked □Positive □Negative □Not checked □Positive □Not checked □Positive □Not checked

	□Negative
	□Not checked
Anti-HBc	□Positive
	□Negative
	□Not checked
Anti-HBc IgM	□Positive
	□Negative
	□Not checked
Anti-HBs	□Positive
	□Negative
	□Not checked
Epstein-Barr Virus antibody IgM (Anti-	□Positive
EBV IgM)	□Negative
	□Not checked
Cytomegalovirus antibody IgM (Anti-CMV	□Positive
IgM)	□Negative
	□Not checked
Anti-nuclear antibody (ANA)	□Positive
	-Level (titer)
	□Negative
	□Not checked
Anti-smooth muscle antibody (ASMA)	□Positive
	□Negative
	□Not checked
Anti-mitochondrial antibody (AMA)	□Positive
	□Negative
	□Not checked
Did the patient develop evidence of	☐Yes – hepatic encephalopathy
decompensated liver disease during or	□Yes – ascites
shortly after COVID-19 illness? (select all	□Yes – variceal hemorrhage
that apply)	□Yes – hepatorenal syndrome
	□No
Was a liver biopsy performed during the	□Yes
COVID-19 hospitalization?	□No
If yes, histologic findings (please list	
abnormal findings in impression section	
of pathology report(s)).	